Intrinsic and environmental mutagenesis drive diversification and persistence of pseudomonas aeruginosa in chronic lung infections

Journal of Infectious Diseases

Volumn 205, Issue 1, 2012, Pages 121-127

  Rodríguez Rojas, Alexandro ^a   Oliver, Antonio ^b   Blázquez, Jesús ^a  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL MUTAGEN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM MUTANT; BIOFILM; CHRONIC LUNG INFECTION; GENE MUTATION; HUMAN; INTRINSIC MUTAGENESIS; LUNG INFECTION; MICROBIAL DIVERSITY; MUTAGENESIS; NONHUMAN; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING;

ADAPTATION, BIOLOGICAL; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GENE-ENVIRONMENT INTERACTION; HUMANS; MUTAGENESIS; MUTATION RATE; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84555178426     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir690     Document Type: Article

References (50)

1. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000; 406:959-64.
2. Hassett DJ, Korfhagen TR, Irvin RT, et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 2010; 14:117-30.
3. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103:8487-92. (Pubitemid 43838482)
4. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60:539-74. (Pubitemid 26303478)
5. Valderrey AD, Pozuelo MJ, Jimenez PA, Macia MD, Oliver A, Rotger R. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 2010; 68:20-7.
6. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44:547-58.
7. Haussler S, Tummler B, Weissbrodt H, Rohde M, Steinmetz I. Smallcolony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999; 29:621-5. (Pubitemid 29439964)
8. Haussler S, Ziegler I, Lottel A, et al. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 2003; 52:295-301. (Pubitemid 36515290)
9. Oliver A, Levin BR, Juan C, Baquero F, Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 2004; 48:4226-33. (Pubitemid 39434879)
10. Thomas SR, Ray A, Hodson ME, Pitt TL. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000; 55:795-7. (Pubitemid 30660910)
11. Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates fromchronically colonized patients with cystic fibrosis. Infect Immun 1994; 62: 596-605. (Pubitemid 24033780)
12. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-4.
13. Gutierrez O, Juan C, Perez JL, Oliver A. Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother 2004; 48:3573-5. (Pubitemid 39129364)
14. Mena A, Smith EE, Burns JL, et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008; 190:7910-17.
15. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49:3382-6. (Pubitemid 41060586)
16. Blazquez J. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 2003; 37:1201-9. (Pubitemid 37372510)
17. Schaber JA, Carty NL, McDonald NA, et al. Analysis of quorum sensing-deficient clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 2004; 53:841-53. (Pubitemid 39238389)
18. Dacheux D, Toussaint B, Richard M, Brochier G, Croize J, Attree I. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect Immun 2000; 68: 2916-24. (Pubitemid 30253872)
19. Rodriguez-Rojas A, Mena A, Martin S, Borrell N, Oliver A, Blazquez J. Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology 2009; 155:1050-7.
20. Smith KC. Spontaneous mutagenesis: experimental, genetic and other factors. Mutat Res 1992; 277:139-62.
21. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005; 49:2276-82. (Pubitemid 40734454)
22. Mateos F, Brock JH, Perez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax 1998; 53:594-600. (Pubitemid 28335522)
23. Ward CG, Bullen JJ, Rogers HJ. Iron and infection: new developments and their implications. J Trauma 1996; 41:356-64. (Pubitemid 26271827)
24. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993; 75:2419-24. (Pubitemid 24008354)
25. Brennan S. Innate immune activation and cystic fibrosis. Paediatr Respir Rev 2008; 9:271-9quiz 279-80.
26. Kohanski MA, Depristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 2010; 37:311-20.
27. Lopez E, Elez M, Matic I, Blazquez J. Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli.Mol Microbiol 2007; 64:83-93. (Pubitemid 46435037)
28. Blazquez J, Gomez-Gomez JM, Oliver A, Juan C, Kapur V, Martin S. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol 2006; 62:84-99. (Pubitemid 44386552)
29. Thi TD, Lopez E, Rodriguez-Rojas A, et al. Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J Antimicrob Chemother 2011; 66:531-8.
30. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Hoiby N. Genetic adaptation of P. aeruginosa during chronic lung infection: strong and weak mutators with heterogenous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 2009; 156:1108-19.
31. Denamur E, Matic I. Evolution of mutation rates in bacteria. Mol Microbiol 2006; 60:820-7.
32. Mena A, Macia MD, Borrell N, et al. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J Bacteriol 2007; 189:3665-8. (Pubitemid 46668834)
33. Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J Bacteriol 2006; 188:7101-10. (Pubitemid 44547615)
34. Boles BR, Thoendel M, Singh PK. Self-generated diversity produces "insurance effects" in biofilm communities. Proc Natl Acad Sci USA 2004; 101:16630-5. (Pubitemid 39557764)
35. Driffield K, Miller K, Bostock JM, O'Neill AJ, Chopra I. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 2008; 61:1053-6. (Pubitemid 351524449)
36. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 2008; 105:12503-8.
37. Xu KD, Stewart PS, Xia F, Huang CT, McFeters GA. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microbiol 1998; 64: 4035-9. (Pubitemid 28463010)
38. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22. (Pubitemid 29289651)
39. Couce A, Blazquez J. Side effects of antibiotics on genetic variability. FEMS Microbiol Rev 2009; 33:531-8.
40. Lee B, Haagensen JA, Ciofu O, Andersen JB, Hoiby N, Molin S. Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 2005; 43:5247-55. (Pubitemid 41484033)
41. Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev 2007; 8:4-7. (Pubitemid 46523785)
42. Perez-Vilar J, Boucher RC. Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease. Free Radic Biol Med 2004; 37:1564-77. (Pubitemid 39349803)
43. Rodriguez-Rojas A, Blazquez J. The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection. J Bacteriol 2009; 191:844-50.
44. Yeung AT, Torfs EC, Jamshidi F, et al. Swarming of Pseudomonas aeruginosa is controlled by a broad spectrum of transcriptional regulators, including MetR. J Bacteriol 2009; 191:5592-602.
45. Eigen M. Viral quasispecies. Sci Am 1993; 269:42-9.
46. Wilke CO. Quasispecies theory in the context of population genetics. BMC Evol Biol 2005; 5:44.
47. Jelsbak L, Johansen HK, Frost AL, et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun 2007; 75:2214-24. (Pubitemid 46744308)
48. Kuipers EJ, Israel DA, Kusters JG, et al. Quasispecies development of Helicobacter pylori observed in paired isolates obtained years apart from the same host. J Infect Dis 2000; 181:273-82. (Pubitemid 30049058)
49. Bull JJ, Wilke CO. Lethal mutagenesis of bacteria. Genetics 2008; 180:1061-70.
50. Cirz RT, Romesberg FE. Controlling mutation: intervening in evolution as a therapeutic strategy. Crit Rev Biochem Mol Biol 2007; 42:341-54. (Pubitemid 47537266)